Acute Graft Rejection

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
TacrolimusN/A1 trial
Active Trials
NCT01265537Completed30Est. Oct 2019
Genomics
GenomicsUK - Oxford
1 program
TruGraf liver gene expressionN/A1 trial
Active Trials
NCT06557564Recruiting471Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GenomicsTruGraf liver gene expression
AstellasTacrolimus

Clinical Trials (2)

Total enrollment: 501 patients across 2 trials

NCT06557564GenomicsTruGraf liver gene expression

Diagnosis of Graft Pathology by TruGraf

Start: Jul 2024Est. completion: Dec 2027471 patients
N/ARecruiting

A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf

Start: Jun 2011Est. completion: Oct 201930 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 501 patients
2 companies competing in this space